Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Adult
Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Breast
/ pathology
Breast Neoplasms
/ mortality
Chemotherapy, Adjuvant
/ statistics & numerical data
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymph Nodes
/ pathology
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Prognosis
Radiotherapy, Adjuvant
/ statistics & numerical data
Receptor, ErbB-2
/ analysis
Receptors, Estrogen
/ analysis
Receptors, Progesterone
/ analysis
Retrospective Studies
Risk Factors
Breast cancer
Node-negative
Prognosis
Recurrence risk
Relapse risk
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
24
09
2019
revised:
10
02
2020
accepted:
24
02
2020
pubmed:
14
4
2020
medline:
9
10
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Because the risk of relapse of node-negative breast cancer (BC) is varying, we evaluated the prognosis of patients with this disease and the factors associated with increased risk of relapse. The clinical charts of patients with BC with evidence of negative nodes and with a potential ≥ 5-year follow-up were retrospectively reviewed. We analyzed 1276 patients. Over a median follow-up of 71.6 months (range, 1-227.2 months), we observed 159 events of relapse or death. The median RFS was 170 months. The median overall survival (OS) was 192 months. At univariate analysis, older age, negative hormonal receptors, larger tumor size and higher proliferation index (Ki67) were associated with worse recurrence-free survival (RFS) and OS (P < .05); higher grading was associated with worse RFS (P = .01). At multivariate analysis for RFS, age, Ki67 and tumor size confirmed their independent prognostic role. At multivariate analysis for OS, age and positive hormonal receptors showed an independent prognostic role. We observed no differences in prognosis between human epidermal growth factor receptor 2 (HER2) positive and triple-negative (TN) BC, but TNBC showed a worse OS compared with luminal-like BC. In node-negative BC, age, hormone receptor status, tumor size and Ki67 were prognostic factors. The TNBC subtype was not associated with poorer prognosis compared with the HER2-positive subtype, but showed a worse OS compared with luminal-like BC.
Sections du résumé
BACKGROUND
Because the risk of relapse of node-negative breast cancer (BC) is varying, we evaluated the prognosis of patients with this disease and the factors associated with increased risk of relapse.
PATIENTS AND METHODS
The clinical charts of patients with BC with evidence of negative nodes and with a potential ≥ 5-year follow-up were retrospectively reviewed.
RESULTS
We analyzed 1276 patients. Over a median follow-up of 71.6 months (range, 1-227.2 months), we observed 159 events of relapse or death. The median RFS was 170 months. The median overall survival (OS) was 192 months. At univariate analysis, older age, negative hormonal receptors, larger tumor size and higher proliferation index (Ki67) were associated with worse recurrence-free survival (RFS) and OS (P < .05); higher grading was associated with worse RFS (P = .01). At multivariate analysis for RFS, age, Ki67 and tumor size confirmed their independent prognostic role. At multivariate analysis for OS, age and positive hormonal receptors showed an independent prognostic role. We observed no differences in prognosis between human epidermal growth factor receptor 2 (HER2) positive and triple-negative (TN) BC, but TNBC showed a worse OS compared with luminal-like BC.
CONCLUSIONS
In node-negative BC, age, hormone receptor status, tumor size and Ki67 were prognostic factors. The TNBC subtype was not associated with poorer prognosis compared with the HER2-positive subtype, but showed a worse OS compared with luminal-like BC.
Identifiants
pubmed: 32279915
pii: S1526-8209(20)30046-X
doi: 10.1016/j.clbc.2020.02.011
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e481-e489Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.